Roche Holding AG Retained Earnings (Accumulated Deficit) 2010-2024 | RHHBY

Roche Holding AG retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $49.800B, a 34.55% increase year-over-year.

  • Roche Holding AG retained earnings (accumulated deficit) for 2024 were $49.8B, a 5.58% increase from 2023.
  • Roche Holding AG retained earnings (accumulated deficit) for 2023 were $47.17B, a 15.61% increase from 2022.
  • Roche Holding AG retained earnings (accumulated deficit) for 2022 were $40.802B, a 9.17% increase from 2021.

Roche Holding AG Retained Earnings (Accumulated Deficit) 2010-2024 | RHHBY

  • Roche Holding AG retained earnings (accumulated deficit) for 2024 were $49.8B, a 5.58% increase from 2023.
  • Roche Holding AG retained earnings (accumulated deficit) for 2023 were $47.17B, a 15.61% increase from 2022.
  • Roche Holding AG retained earnings (accumulated deficit) for 2022 were $40.802B, a 9.17% increase from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$796.4B
Johnson & Johnson (JNJ)$379.5B
AbbVie (ABBV)$306B
Novo Nordisk (NVO)$260.6B
Novartis AG (NVS)$234.2B
Merck (MRK)$196.7B
Sanofi (SNY)$128.6B
Pfizer (PFE)$125.6B
Bayer (BAYRY)$23.7B
Innoviva (INVA)$1.1B